


## SARS-CoV-2 nsp14-IN-1

Cat. No.:	HY-150680
CAS No.:	2816165-02-1
Molecular Formula:	C <sub>20</sub> H <sub>20</sub> N <sub>6</sub> O <sub>5</sub> S
Molecular Weight:	456.48
Target:	SARS-CoV; Histone Methyltransferase; DNA Methyltransferase
Pathway:	Anti-infection; Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	SARS-CoV-2 nsp14-IN-1 (Compound 3) is a prototypic bisubstrate inhibitor of SARS-CoV-2 Nsp14 MTase with an IC <sub>50</sub> value of 0.061 μM. SARS-CoV-2 nsp14-IN-1 (Compound 3) has an excellent selectivity profile over a panel of human methyltransferases, can against a panel of 10 human MTases including histone lysine, proteinarginine, and DNA and RNA MTases <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> 0.061 μM (Nsp14 MTase) <sup>[1]</sup>
<b>In Vitro</b>	SARS-CoV-2 nsp14-IN-1 (Compound 3) displays an excellent selectivity profile for Nsp14 MTase With an IC <sub>50</sub> value of 0.061 μM. SARS-CoV-2 nsp14-IN-1 (Compound 3) shows low passive diffusion rates in PAMPA. SARS-CoV-2 nsp14-IN-1 (Compound 3) does not suffer major metabolic liabilities in human plasma and liver S9 fractions <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Eunkyung Jung, et al. Bisubstrate Inhibitors of Severe Acute Respiratory Syndrome Coronavirus-2 Nsp14 Methyltransferase. ACS Med. Chem. Lett. July 22, 2022.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA